ATI INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ATI INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $4.04B | Feb 27, 2014 |
| FY2012 | Dec 31, 2012 | $5.03B | Feb 28, 2013 |
| FY2011 | Dec 31, 2011 | $5.18B | Feb 27, 2012 |
| FY2011 | Dec 31, 2010 | $4.05B | Feb 27, 2012 |
| FY2011 | Dec 31, 2009 | $3.05B | Feb 27, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $4.59B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $4.36B | Feb 20, 2026 |
| FY2023 | Dec 31, 2023 | $1.06B | Feb 23, 2024 |
| FY2023 | Oct 1, 2023 | $1.03B | Feb 23, 2024 |
| FY2023 | Jul 2, 2023 | $1.05B | Feb 23, 2024 |
| FY2023 | Apr 2, 2023 | $1.04B | Feb 23, 2024 |
| FY2023 | Jan 1, 2023 | $1.01B | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $3.84B | Feb 24, 2023 |
| FY2023 | Oct 2, 2022 | $1.03B | Feb 23, 2024 |
| FY2023 | Jul 3, 2022 | $959.50M | Feb 23, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $1.10B | Feb 28, 2013 |
| FY2012 | Sep 30, 2012 | $1.22B | Feb 28, 2013 |
| FY2012 | Jun 30, 2012 | $1.36B | Feb 28, 2013 |
| FY2012 | Mar 31, 2012 | $1.35B | Feb 28, 2013 |
| FY2011 | Dec 31, 2011 | $1.25B | Feb 27, 2012 |
| FY2011 | Sep 30, 2011 | $1.35B | Feb 27, 2012 |
| FY2011 | Jun 30, 2011 | $1.35B | Feb 27, 2012 |
| FY2011 | Mar 31, 2011 | $1.23B | Feb 27, 2012 |
| FY2010 | Dec 31, 2010 | $1.04B | Feb 28, 2011 |
| FY2010 | Sep 30, 2010 | $1.06B | Feb 28, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $1.01B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $898.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $802.60M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $714.20M | Feb 21, 2025 |
| FY2022 | Dec 31, 2022 | $714.20M | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | $333.20M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $333.20M | Feb 24, 2023 |
| FY2020 | Dec 31, 2020 | $45.20M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $38.10M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $74.70M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $404.30M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $367.80M | Feb 20, 2026 |
| FY2023 | Dec 31, 2023 | $145.70M | Feb 23, 2024 |
| FY2023 | Oct 1, 2023 | $90.20M | Feb 23, 2024 |
| FY2023 | Jul 2, 2023 | $90.40M | Feb 23, 2024 |
| FY2023 | Apr 2, 2023 | $84.50M | Feb 23, 2024 |
| FY2023 | Jan 1, 2023 | $193.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $130.90M | Feb 24, 2023 |
| FY2023 | Oct 2, 2022 | $76.90M | Feb 23, 2024 |
| FY2023 | Jul 3, 2022 | $6.70M | Feb 23, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $640.90M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $608.90M | Feb 20, 2026 |
| FY2023 | Dec 31, 2023 | $108.30M | Feb 23, 2024 |
| FY2023 | Oct 1, 2023 | $125.20M | Feb 23, 2024 |
| FY2023 | Jul 2, 2023 | $120.30M | Feb 23, 2024 |
| FY2023 | Apr 2, 2023 | $112.60M | Feb 23, 2024 |
| FY2023 | Jan 1, 2023 | $108.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $287.30M | Feb 24, 2023 |
| FY2023 | Oct 2, 2022 | $113.20M | Feb 23, 2024 |
| FY2023 | Jul 3, 2022 | $17.20M | Feb 23, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $21.30M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $19.60M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $20.70M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $16.30M | Feb 21, 2025 |
| FY2022 | Dec 31, 2022 | $16.30M | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | $16.50M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $16.50M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $14.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $17.80M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $22.70M | Feb 26, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $365.10M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $342.30M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $328.10M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $297.50M | Feb 21, 2025 |
| FY2022 | Dec 31, 2022 | $297.50M | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | $226.90M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $226.90M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $201.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $267.20M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $268.20M | Feb 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $614.30M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $407.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $85.90M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $224.90M | Feb 21, 2025 |
| FY2022 | Dec 31, 2022 | $224.90M | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | $16.10M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $16.10M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $166.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $230.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $392.80M | Feb 26, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $5.10B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $5.23B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $4.99B | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $4.45B | Feb 21, 2025 |
| FY2022 | Dec 31, 2022 | $4.45B | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | $4.29B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $4.29B | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $4.03B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $5.63B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $5.50B | Feb 26, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $3.18B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $3.28B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.50B | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $3.29B | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $3.29B | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $3.45B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.39B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $3.44B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.51B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $3.34B | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $1.80B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $1.85B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.37B | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $1.05B | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $1.05B | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $685.60M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $521.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.09B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.89B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.74B | Feb 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $225.20M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $227.20M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $227.20M | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $227.20M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $227.20M | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $227.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $240.70M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $525.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $534.70M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $531.40M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $468.70M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $64.30M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($70.10M) | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | ($480.90M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $176.90M | Feb 24, 2023 |
| FY2023 | Jan 2, 2022 | ($777.70M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $72.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $106.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.68B | Feb 26, 2021 |
| FY2021 | Dec 31, 2018 | $1.43B | Feb 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $416.70M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $721.20M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $743.90M | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $584.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $584.00M | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $687.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $645.90M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $490.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $382.00M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $141.60M | Feb 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 2 | Feb 20, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Feb 23, 2024 |
| FY2023 | Oct 1, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Jul 2, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Apr 2, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Jan 1, 2023 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | 1 | Feb 24, 2023 |
| FY2023 | Oct 2, 2022 | 0 | Feb 23, 2024 |
| FY2023 | Jul 3, 2022 | 0 | Feb 23, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 2 | Feb 20, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Oct 1, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Jul 2, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Apr 2, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Jan 1, 2023 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | 0 | Feb 24, 2023 |
| FY2023 | Oct 2, 2022 | 0 | Feb 23, 2024 |
| FY2023 | Jul 3, 2022 | 0 | Feb 23, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 135.93M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 141.39M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 126.88M | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | 128.27M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | 128.27M | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | 127.25M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 126.82M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 126.09M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 125.68M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 125.86M | Feb 28, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $0 | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $25.80M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $66.50M | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $77.10M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $76.90M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $76.50M | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $74.70M | Feb 27, 2014 |
| FY2012 | Dec 31, 2010 | $70.80M | Feb 28, 2013 |